The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PHVS | -12.83% | N/A | N/A | -25% |
| S&P | +13.35% | +91.49% | +13.87% | +73% |
Pharvaris NV operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. Its PHA121 program is designed to treat all sub-types of hereditary angioedema. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Hans Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.12M | -58.1% |
| Market Cap | $959.08M | -5.2% |
| Market Cap / Employee | $8.41M | 0.0% |
| Employees | 114 | 37.3% |
| Net Income | -$51.59M | -61.2% |
| EBITDA | -$45.68M | -23.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $234.27M | -36.4% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.55M | 1083.2% |
| Short Term Debt | $0.19M | 83.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -58.80% | -16.6% |
| Return On Invested Capital | -35.03% | -1.9% |
| Q4 2024 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$34.73M | -40.2% |
| Operating Free Cash Flow | -$34.57M | -39.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.80 | 3.14 | 2.57 | 3.94 | 51.06% |
| Price to Tangible Book Value | 2.80 | 3.14 | 2.57 | 3.45 | 32.34% |
| Enterprise Value to EBITDA | -17.89 | -18.07 | -12.52 | -15.96 | -24.27% |
| Return on Equity | -58.2% | -41.4% | -51.9% | -64.0% | 41.66% |
| Total Debt | $0.13M | $0.89M | $0.80M | $0.74M | 394.78% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
